Zobrazeno 1 - 10
of 150
pro vyhledávání: '"R. von Roemeling"'
Autor:
G. Garcia-Manero, E. S. Winer, D. J. DeAngelo, S. Tarantolo, D. A. Sallman, J. Dugan, S. Groepper, A. Giagounidis, K. Götze, K. H. Metzeler, C.-C. Li, L. Zhou, E. Martinez, M. Lane, R. von Roemeling, M. Bohme, A. S. Kubasch, A. Verma, U. Platzbecker
Publikováno v:
HemaSphere, Vol 6, Pp 30-31 (2022)
Externí odkaz:
https://doaj.org/article/5d23475a3923405da106a5b934d452cc
Autor:
A. Ugolkov, M. Pilichowska, C.-C. Li, R. C. Hok, M. Samson, M. Lane, R. Von Roemeling, R. Martell
Publikováno v:
HemaSphere, Vol 6, Pp 372-373 (2022)
Externí odkaz:
https://doaj.org/article/1987c72038c246729d7f60c8e90f03c5
Autor:
E. Joffe, G. Nowakowski, H. Tun, A. Rosenthal, M. Lunning, R. Ramchandren, C.-C. Li, L. Zhou, E. Martinez, R. von Roemeling, R. Earhart, M. McMahon, I. Isufi, L. Leslie
Publikováno v:
HemaSphere, Vol 6, Pp 1011-1012 (2022)
Externí odkaz:
https://doaj.org/article/06334392b0a64cde9f47e9d7e5d5e893
Autor:
Lori A. Leslie, Allison C. Rosenthal, Han W. Tun, Radhakrishnan Ramchandren, R. von Roemeling, G.S. Nowakowski, Erel Joffe, Monica Mead, Elizabeth Ferreira Martinez, M. Lunning
Publikováno v:
Hematological Oncology. 39
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Frances A. Shepherd, R. von Roemeling, Armando Santoro, Silvia Novello, Wallace Akerley, Alan Sandler, J. von Pawel, David R. Spigel, Adolfo Favaretto, Lecia V. Sequist, Sergey Orlov, Hamim Zahir, Rodryg Ramlau, Dale Shuster, Vera Hirsh, Fabrice Barlesi, Qiang Wang, G.V. Scagliotti, Brian Schwartz
Publikováno v:
Pneumologie. 68
Subpopulation n HR (95% CI) P Value Median PFS, months Response Rate Tivantinib Placebo Tivantinib Placebo ITT 1,048 0.74 (0.64-0.85) < .0001 3.6 1.9 10.3% 6.5% EGFR genotype Wildtype 937 0.72 (0.62-0.83) < .0001 2.7 1.9 4.7% 2.4% KRAS genotype Wildt
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 13:175-180
Neutrophil elastase is involved in the pathogenesis of several pulmonary diseases; a strategy for monitoring in vivo elastase activity is to measure changes in biochemical markers. The objective of this study was to determine whether differences in t
Autor:
R Vescio, J Viallet, J. Treat, R. von Roemeling, J. von Pawel, A Arcenas, Bengt Bergman, Gary Richardson, T W Butler, P I Clark, D Dunlop, Denis C. Talbot, Vera Hirsh, Ian N. Olver, Michael Boyer, Joseph Ayoub, L O Elisson, U. Gatzemeier, A Rey
Publikováno v:
Journal of Clinical Oncology. 18:1351-1359
PURPOSE: A phase III trial, Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non–Small-Cell Lung Tumors (CATAPULT I), was designed to determine the efficacy and safety of tirapazamine plus cisplatin for the treatment of non
Autor:
S. Coates, Omar Eton, R. von Roemeling, A. C. Buzaid, T. Simmons, N. Papadopoulos, A. Y. Bedikian, J. Neefe, S. S. Legha
Publikováno v:
Annals of Oncology. 8:363-367
Summary Purpose A phase II study was undertaken to determine the efficacy of tirapazamine (TPZ) combined with cisplatin (cDDP) in patients with metastatic melanoma. Patients and methods Between June 1994 and November 1995, 48 patients with metastatic
Autor:
Keith C. Bible, Laura A. Marlow, R. von Roemeling, Michael G. Heckman, John A. Copland, J. T. Wadsworth, Marcia S. Brose, Michael E. Menefee, Manisha H. Shah, Robert C. Smallridge, Yariv Houvras, Joshua P. Klopper, Ann Wild Gramza
A phase 1 study was initiated to determine the safety, potential effectiveness, and maximal tolerated dose and recommended phase 2 dose of efatutazone and paclitaxel in anaplastic thyroid cancer.Patients received efatutazone (0.15, 0.3, or 0.5 mg) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a49d450abd016af06f7a068050c7a294
https://europepmc.org/articles/PMC3667260/
https://europepmc.org/articles/PMC3667260/